摘要
目的探究阿帕替尼联合替吉奥治疗晚期胃癌的有效性和安全性。方法研究选取的研究对象为46例行胃癌治疗的患者,根据治疗方式不同进行分组,分别为对照组与实验组,分别为22例与24例,对照组给予替吉奥治疗,实验组给予阿帕替尼联合替吉奥治疗,对比两组患者的疗效、生活质量以及治疗前后营养评分。结果对比两组患者的治疗有效率,实验组高于对照组,组间差异有统计学意义(P<0.05)。对比两组患者的生活质量与营养评分,实验组明显优于对照组,组间差异有统计学意义(P <0.05)。结论阿帕替尼联合替吉奥治疗癌症晚期,提高了患者的营养状况,改善了患者的生活质量,具有有效性及安全性,有利于患者的治疗。
Objective To investigate the efficacy and safety of apatinib combined with tegafur gimeracil oteracil potassium in the treatment of advanced gastric cancer.Methods 46 patients with gastric cancer were divided into two groups:control group and experimental group,22 cases and 24 cases,respectively.The patients in the experimental group were treated with apatinib combined with tegafur gimeracil oteracil potassium.The curative effect,quality of life and nutritional score before and after treatment were compared between the two groups.Results The efficiency of the experimental group was higher than that of the control group,and there was a significant difference between the two groups(P<0.05).Comparing the quality of life and nutrition score of the two groups,the experimental group was significantly better than the control group,and there was a significant difference between the two groups(P<0.05).Conclusion Apatinib combined with tegafur gimeracil oteracil potassium in the treatment of advanced cancer can improve the nutritional status of patients,improve the quality of life of patients,and is effective and safe,which is conducive to the treatment of patients.
作者
刘均港
LIU Jungang(Second Department of Internal Medicine,Zaozhuang Mining Group Zaozhuang Hospital,Zaozhuang Shandong 277100,China)
出处
《中国继续医学教育》
2019年第5期131-133,共3页
China Continuing Medical Education
关键词
阿帕替尼
替吉奥
晚期
胃癌
有效性
安全性
apatinib
tegafur gimeracil oteracil potassium
advanced stage
gastric cancer
efficacy
safety
